CSDX Form 8-K Summary (Oct 30, 2025)

CS Diagnostics Corp. (CSDX) announced a key capital restructuring event:

• Conversion of all outstanding Series B Preferred Stock held by affiliates (CS Interpharm and CS Diagnostics Pharma) into Common Stock.
• Resulted in the issuance of 112,652,000 Common Shares.

This conversion is strategic, intended to align capital structures in preparation for consolidated financial reporting for the fiscal year ending December 31, 2025.

The consolidation will integrate the income and revenue streams from subsidiaries directly into CSDX’s